补肺益肾方Ⅲ号有效部位组合对 COPD 大鼠气道黏液高分泌的抑制作用及机制：与 EGFR/MAPK 信号通路有关。
Effective-compound combination of Bufei Yishen formula III combined with ER suppress airway mucus hypersecretion in COPD rats: via EGFR/MAPK signaling.
机构信息
Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Co-construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan and Education Ministry of P.R., Henan University of Chinese Medicine, Zhengzhou, Henan 450046, China.
Traditional Chinese Medicine (ZHONG JING) School, Henan University of Chines Medicine, Zhengzhou, Henan 450046, China.
出版信息
Biosci Rep. 2023 Nov 30;43(11). doi: 10.1042/BSR20222669.
BACKGROUND
The aim of this study was to explore the combined efficacy ofeffective-component compatibility of Bufei Yishen formula III (ECC-BYF III) and exercise rehabilitation (ER) in inhibiting airway mucus hypersecretion in a chronic obstructive pulmonary disease (COPD) rat model.
METHODS
A total of 48 SD rats were divided into control, model, acetylcysteine (NAC), ECC-BYF III, ER, and ECC-BYF III + ER groups (n=8). COPD rats were exposed to cigarette smoke and bacteria for 8 weeks and administered various treatments over the next eight weeks. Rats were euthanized at week 17 after pulmonary function testing. Pathological examination of lung tissues was performed. IL-6 and IL-10 levels were measured in bronchoalveolar lavage fluid (BALF) and protein levels of MUC5AC, MUC5B, AQP-5, EGFR, ERK, JNK, and p38 were measured in lung tissues.
RESULTS
Improved pulmonary function and pathological changes were observed in ECC-BYF III, ECC-BYF III + ER, and NAC groups. ECC-BYF III and ECC-BYF III + ER had greater mean alveolar number (MAN) compared with NAC. Lung inflammation and goblet cell generation were reduced and MUC5AC, MUC5B and AQP-5 expressions were lower in all treatment groups. ECC-BYF III has more significant effect on MUC5AC than ER and NAC. ECC-BYFIII + ER had a greater effect on suppressing IL-6 in BALF compared with other treatments. ECC-BYFIII, ER, and ECC-BYF III + ER reduced EGFR, ERK, JNK, and p38 phosphorylated protein levels. ECC-BYFIII+ER had a greater effect on p-JNK and p-p38 than ECC-BYFIII and NAC.
CONCLUSION
ECC-BYF III, ER, and ECC-BYF III + ER have efficacy in inhibiting airway mucus hypersecretion with improved pulmonary function and pathological changes. ECC-BYF III had a greater effect in improving MAN and MUC5AC in lung tissue. ECC-BYF III+ER had a greater effect in alleviating pulmonary pathology and inflammation. These effects may be mediated by inhibition of the EGFR/MAPK pathway.
背景
本研究旨在探讨补肺益肾方 III 号（ECC-BYF III）有效成分配伍与运动康复（ER）联合抑制慢性阻塞性肺疾病（COPD）大鼠模型气道黏液高分泌的疗效。
方法
将 48 只 SD 大鼠分为对照组、模型组、乙酰半胱氨酸（NAC）组、ECC-BYF III 组、ER 组和 ECC-BYF III+ER 组（n=8）。将 COPD 大鼠暴露于香烟烟雾和细菌中 8 周，并在接下来的 8 周内给予各种治疗。在肺功能测试后第 17 周处死大鼠。对肺组织进行病理学检查。测量支气管肺泡灌洗液（BALF）中 IL-6 和 IL-10 水平以及肺组织中 MUC5AC、MUC5B、AQP-5、EGFR、ERK、JNK 和 p38 的蛋白水平。
结果
ECC-BYF III、ECC-BYF III+ER 和 NAC 组的肺功能和病理变化得到改善。ECC-BYF III 和 ECC-BYF III+ER 组的平均肺泡数（MAN）较 NAC 组更高。所有治疗组的肺炎症和杯状细胞生成减少，MUC5AC、MUC5B 和 AQP-5 表达降低。ECC-BYF III 对 MUC5AC 的抑制作用强于 ER 和 NAC。ECC-BYF III+ER 组 BALF 中 IL-6 的抑制作用强于其他治疗组。ECC-BYF III、ER 和 ECC-BYF III+ER 降低了 EGFR、ERK、JNK 和 p38 磷酸化蛋白水平。ECC-BYF III+ER 组对 p-JNK 和 p-p38 的抑制作用强于 ECC-BYF III 和 NAC。
结论
ECC-BYF III、ER 和 ECC-BYF III+ER 具有抑制气道黏液高分泌、改善肺功能和病理变化的作用。ECC-BYF III 对改善肺组织中 MAN 和 MUC5AC 的作用更强。ECC-BYF III+ER 对减轻肺病理和炎症的作用更强。这些作用可能是通过抑制 EGFR/MAPK 通路介导的。
Zotero 插件